CA2149120A1 - Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof - Google Patents

Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof

Info

Publication number
CA2149120A1
CA2149120A1 CA002149120A CA2149120A CA2149120A1 CA 2149120 A1 CA2149120 A1 CA 2149120A1 CA 002149120 A CA002149120 A CA 002149120A CA 2149120 A CA2149120 A CA 2149120A CA 2149120 A1 CA2149120 A1 CA 2149120A1
Authority
CA
Canada
Prior art keywords
monoclonal antibody
vascular endothelium
tumor vascular
specifically binds
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002149120A
Other languages
French (fr)
Other versions
CA2149120C (en
Inventor
Pilar Garin-Chesa
Wolfgang J. Rettig
Lloyd J. Old
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Memorial Sloan Kettering Cancer Center
Original Assignee
Pilar Garin-Chesa
Wolfgang J. Rettig
Lloyd J. Old
Ludwig Institute For Cancer Research
Memorial Sloan-Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pilar Garin-Chesa, Wolfgang J. Rettig, Lloyd J. Old, Ludwig Institute For Cancer Research, Memorial Sloan-Kettering Cancer Center filed Critical Pilar Garin-Chesa
Publication of CA2149120A1 publication Critical patent/CA2149120A1/en
Application granted granted Critical
Publication of CA2149120C publication Critical patent/CA2149120C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/857—Fish; fish eggs; shell fish; crustacea

Abstract

The invention involves monoclonal antibodies which specifically bind to a cell surface antigen characteristic of tumor vascular endothelium. The antigen, referred to as endosialin, is a glycoproteine and has a molecular weight of about 165 kDa as determined by SDS-PAGE. The protein portion of the molecule has a molecular weight of about 95 kDa. Also disclosed are various uses of the monoclonal antibody and the antigen.
CA002149120A 1992-11-13 1993-11-09 Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof Expired - Lifetime CA2149120C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/976,405 1992-11-13
US07/976,405 US5342757A (en) 1992-11-13 1992-11-13 Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
PCT/US1993/010773 WO1994011023A1 (en) 1992-11-13 1993-11-09 Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof

Publications (2)

Publication Number Publication Date
CA2149120A1 true CA2149120A1 (en) 1994-05-26
CA2149120C CA2149120C (en) 2005-09-27

Family

ID=25524065

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002149120A Expired - Lifetime CA2149120C (en) 1992-11-13 1993-11-09 Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof

Country Status (12)

Country Link
US (2) US5342757A (en)
EP (1) EP0673255B1 (en)
JP (1) JP3541296B2 (en)
AT (1) ATE204480T1 (en)
AU (1) AU671884B2 (en)
CA (1) CA2149120C (en)
DE (1) DE69330643T2 (en)
DK (1) DK0673255T3 (en)
ES (1) ES2161751T3 (en)
GR (1) GR3036906T3 (en)
PT (1) PT673255E (en)
WO (1) WO1994011023A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
CA2452130A1 (en) * 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
EP0746613B1 (en) * 1994-03-08 2006-05-24 Memorial Sloan-Kettering Cancer Center Recombinant humanized anti-fb5 antibodies
US5536641A (en) * 1994-05-17 1996-07-16 Memorial Sloane Kittering Cancer Center Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1 and uses thereof for detection of, and isolation of, vascular endothelial cells
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
BR9909420A (en) 1998-03-31 2001-09-25 Du Pont Pharm Co Compound, kit, diagnostic or therapeutic metallopharmaceutical composition, ultrasound contrast agent composition, therapeutic radiopharmaceutical composition and diagnostic radiopharmaceutical composition
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000035492A2 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7951061B2 (en) 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US7731648B2 (en) 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
EP1534331B1 (en) * 2002-06-21 2014-10-29 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
ATE493440T1 (en) * 2003-03-04 2011-01-15 Kirin Brewery ENDOTHELIAL CELL-SPECIFIC ANTIBODIES AND THEIR USE
DE602005022757D1 (en) * 2004-12-03 2010-09-16 Morphotek Inc USE OF ENDOSIALINBINDING PROTEINS FOR ISOLATING ENDOSIALINPOSITIVE CELLS
CA2607455A1 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
DK2137217T3 (en) * 2007-04-05 2014-03-17 Morphotek Inc Methods of inhibiting the binding of endosialin to ligands
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
SE535982C2 (en) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab A new vaccine that attacks tumor vessels as an effective tool in tumor therapy
WO2012050883A1 (en) 2010-09-29 2012-04-19 Morphotek, Inc. Engineered human endosialin-expressing rodents
EP2831114B1 (en) * 2012-03-30 2019-05-08 Eisai R&D Management Co., Ltd. Tem-1 diagnostic antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0746613B1 (en) * 1994-03-08 2006-05-24 Memorial Sloan-Kettering Cancer Center Recombinant humanized anti-fb5 antibodies

Also Published As

Publication number Publication date
EP0673255B1 (en) 2001-08-22
DK0673255T3 (en) 2001-12-10
AU671884B2 (en) 1996-09-12
PT673255E (en) 2002-02-28
CA2149120C (en) 2005-09-27
DE69330643D1 (en) 2001-09-27
ATE204480T1 (en) 2001-09-15
GR3036906T3 (en) 2002-01-31
EP0673255A4 (en) 1996-08-21
DE69330643T2 (en) 2002-07-04
WO1994011023A1 (en) 1994-05-26
ES2161751T3 (en) 2001-12-16
AU5596594A (en) 1994-06-08
US5437865A (en) 1995-08-01
US5342757A (en) 1994-08-30
JPH08505764A (en) 1996-06-25
JP3541296B2 (en) 2004-07-07
EP0673255A1 (en) 1995-09-27

Similar Documents

Publication Publication Date Title
CA2149120A1 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof
WO1994004691A3 (en) Dimer and multimer forms of single chain polypeptides
CA2006865A1 (en) Humanized immunoglobulins and their production and use
CA2182013A1 (en) Humanized antibodies against leukocyte adhesion molecule vla-4
WO1994029451A3 (en) Humanised antibodies
CA2172376A1 (en) Antibodies to cd40
ES2106195T3 (en) IGG AGLYCOSILATED ANTIBODY ANTI CD3.
LU91167I2 (en) Bevacizumab as present in the AVASTIN product approved by the EMEA, including the various forms and post-translational modifications of Bevacizumab which is present there, as well as the immunological and immunochemical variants thereof (AVASTIN).
CA2265484A1 (en) Tumor homing molecules, conjugates derived therefrom, and methods of using same
ATE223229T1 (en) COMPOSITIONS OF CONJUGATES OF THE STABLE, ACTIVE, HUMAN OB PROTEIN WITH THE FC CHAIN OF IMMUNOGLOBULINS AND RELATED METHODS
ATE177758T1 (en) SYNTHETIC PEPTIDES, ANTIBODIES AGAINST THEM AND THEIR USE
WO1999003987A3 (en) Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy
AU5215090A (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
EP0876396A4 (en) MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
AU1125192A (en) Fusion proteins for prodrug activation, the preparation and use thereof
ATE285418T1 (en) HUMANIZED ANTIBODY SPECIFIC TO THE SURFACE ANTIGEN PRE-S1 OF HBV AND ITS PREPARATION
AU2032988A (en) A genus-specific listeria antigen identified by monoclonal antibodies
CA2107329A1 (en) Anti-Human Immunodeficiency Virus Recombinant Antibodies
AU7144787A (en) Tumor-associated antigen (mol wt 68,000-48000; 40,000-80000; 28000-32000; 16000-19000)
EP0397419A3 (en) Novel tumor-associated antigen, antibodies, compositions and uses therefor
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
AU5790390A (en) A novel tumor associated antigen
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
KR930701201A (en) Immunoreactive compounds

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20131112